IDH2 and glioblastoma: According to the RANO categories for EOR in IDH-wt glioblastoma, SMR/CR (IDH-wt astrocytoma 41 patients (25.6%); IDH-wt glioblastoma 65 patients (31.5%)), NTR (IDH-wt astrocytoma: 9 patients (5.6%); IDH-wt glioblastoma: 40 patients (19.7%)) and STR (IDH-wt astrocytoma: 40 patients (25.0%); IDH-wt glioblastoma: 24 patients (11.8%)) were achieved more often in IDH-wt glioblastoma (CR+NTR: p = 0.0094; STR: p = 0.014).